We rank companies based on fund manager, research analyst and news sentiment
ATHE

Alterity Therapeutics
ATHE

$2.13
7.84%
 

About: Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

Employees: 11

0
Funds holding %
of 6,474 funds
Analysts bullish %
0
News positive %
of 3 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

39% more capital invested

Capital invested by funds: $144K [Q3] → $200K (+$56.1K) [Q4]

0% more funds holding

Funds holding: 8 [Q3] → 8 (+0) [Q4]

0.0% more ownership

Funds ownership: 0.0% [Q3] → 0.0% (+0.0%) [Q4]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$4
88%
upside
Avg. target
$4
88%
upside
High target
$4
88%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Benchmark
Robert Wasserman
88%upside
$4
Speculative Buy
Reiterated
7 Mar 2024

Financial journalist opinion

Based on 3 articles about ATHE published over the past 30 days